Free Trial

Organogenesis (ORGO) Competitors

Organogenesis logo
$4.40 -0.06 (-1.35%)
Closing price 04:00 PM Eastern
Extended Trading
$4.44 +0.04 (+1.00%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORGO vs. HRMY, ADPT, SPRY, CNTA, TARS, BEAM, SRPT, ARQT, IMCR, and SDGR

Should you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), ARS Pharmaceuticals (SPRY), Centessa Pharmaceuticals (CNTA), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Arcutis Biotherapeutics (ARQT), Immunocore (IMCR), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry.

Organogenesis vs. Its Competitors

Organogenesis (NASDAQ:ORGO) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Organogenesis has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 33.0% of Organogenesis shares are held by insiders. Comparatively, 23.6% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Harmony Biosciences had 4 more articles in the media than Organogenesis. MarketBeat recorded 7 mentions for Harmony Biosciences and 3 mentions for Organogenesis. Harmony Biosciences' average media sentiment score of 0.94 beat Organogenesis' score of 0.35 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Harmony Biosciences
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Organogenesis currently has a consensus target price of $6.00, suggesting a potential upside of 36.36%. Harmony Biosciences has a consensus target price of $51.33, suggesting a potential upside of 49.53%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Organogenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Harmony Biosciences
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

Harmony Biosciences has a net margin of 20.53% compared to Organogenesis' net margin of -3.46%. Harmony Biosciences' return on equity of 24.32% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis-3.46% -4.00% -2.26%
Harmony Biosciences 20.53%24.32%15.92%

Harmony Biosciences has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$482.04M1.16$860K-$0.17-25.88
Harmony Biosciences$714.73M2.76$145.49M$2.6213.10

Summary

Harmony Biosciences beats Organogenesis on 15 of the 17 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORGO vs. The Competition

MetricOrganogenesisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$565.77M$2.43B$5.56B$9.04B
Dividend YieldN/A1.79%5.25%4.03%
P/E Ratio-25.889.3827.1820.14
Price / Sales1.16765.58440.78137.14
Price / Cash21.37164.1737.5058.41
Price / Book2.114.698.085.60
Net Income$860K$31.26M$3.16B$248.43M
7 Day Performance1.15%6.81%3.77%5.15%
1 Month Performance26.80%4.12%3.90%7.62%
1 Year Performance53.85%4.05%34.22%21.56%

Organogenesis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGO
Organogenesis
4.2874 of 5 stars
$4.40
-1.3%
$6.00
+36.4%
+60.4%$565.77M$482.04M-25.88950
HRMY
Harmony Biosciences
4.8116 of 5 stars
$31.60
-1.2%
$53.63
+69.7%
-0.8%$1.84B$714.73M12.06200News Coverage
Analyst Forecast
ADPT
Adaptive Biotechnologies
3.4352 of 5 stars
$11.65
-1.2%
$10.57
-9.3%
+237.0%$1.79B$178.96M-12.14790
SPRY
ARS Pharmaceuticals
3.0794 of 5 stars
$17.45
-4.1%
$31.00
+77.7%
+83.4%$1.79B$89.15M-109.0690High Trading Volume
CNTA
Centessa Pharmaceuticals
2.6282 of 5 stars
$13.14
+0.1%
$27.89
+112.2%
+43.3%$1.75B$6.85M-7.26200
TARS
Tarsus Pharmaceuticals
2.1391 of 5 stars
$40.51
+0.4%
$66.67
+64.6%
+46.0%$1.70B$182.95M-14.8450Positive News
BEAM
Beam Therapeutics
2.6909 of 5 stars
$17.01
+1.3%
$48.75
+186.6%
-10.0%$1.69B$63.52M-3.69510News Coverage
Gap Up
SRPT
Sarepta Therapeutics
4.7609 of 5 stars
$17.10
-0.1%
$60.88
+256.0%
-87.1%$1.68B$1.90B-6.361,372Trending News
Analyst Forecast
High Trading Volume
ARQT
Arcutis Biotherapeutics
1.2132 of 5 stars
$14.02
+2.0%
$18.80
+34.1%
+41.9%$1.64B$196.54M-13.48150
IMCR
Immunocore
1.1702 of 5 stars
$31.38
+0.8%
$58.89
+87.7%
-9.7%$1.56B$310.20M-72.98320
SDGR
Schrodinger
2.6805 of 5 stars
$20.12
-2.4%
$32.80
+63.0%
+5.7%$1.51B$207.54M-7.65790High Trading Volume

Related Companies and Tools


This page (NASDAQ:ORGO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners